<DOC>
	<DOC>NCT00876694</DOC>
	<brief_summary>This study is designed to collect long term safety data of indacaterol (300 µg o.d.) in Japanese patients with moderate to severe COPD. Data from this study will be used for the registration of indacaterol in Japan.</brief_summary>
	<brief_title>Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1. Diagnosis of COPD (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines) and: Smoking history of at least 20 packyears Postbronchodilator FEV1 &lt;80% and ≥30% of the predicted normal value Postbronchodilator FEV1/FVC (forced vital capacity) &lt;70% 1. Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the runin period 2. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1 3. Patients with concomitant pulmonary disease 4. Patients with a history of asthma 5. Patients with diabetes Type I or uncontrolled diabetes Type II 6. Any patient with lung cancer or a history of lung cancer 7. Patients with a history of certain cardiovascular comorbid conditions 8. Patients who have been exposed to indacaterol previously. (Except for any patient who enrolled in Study CQAB149B1302) Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>COPD, Chronic Obstructive Pulmonary Disease, Indacaterol, long acting β2-agonist</keyword>
</DOC>